Nuvation Bio
NYSE: NUVBNew York, US · Founded 2018 · Incorporated in Delaware · 5 known investors
Find your way into Nuvation Bio
781 people in our graph share verified history with the Nuvation Bio team — schools, employers, funds. One of them is your warm intro.
Deborah Carrillounlockedknows Stephen Dang · together at University of California, Berkeley - School of Law (overlapped)
×2knows the team · via Latham & Watkins LLP
×6knows the team · via University of Paris I: Panthéon-Sorbonne
knows the team · via University of New Hampshire
×2knows the team · via University of California, Berkeley - School of Law
Nuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients. Founded in 2018, it became a commercial-stage company in 2025.
Founders & leadership
Nuvation Bio was founded in 2018 by David Hung and David Hung, M.D..
DH
David HunginFounderDavid Hung founded Nuvation Bio in 2018 after founding Medivation in 2003, where he identified and led development of multiple oncology programs including the prostate cancer drug enzalutamide before Medivation's acquisition by Pfizer for $14.3B in 2016. Earlier in his career, he served as CEO of Pro•Duct Health, a medical device startup he founded, and trained as a hematologist-oncologist.
DH
David Hung, M.D.inFounder, President and CEODavid Hung is founder, President and CEO of Nuvation Bio, a global oncology company developing novel cancer therapies. He previously founded Medivation in 2003, which he led through the development and FDA approval of multiple oncology drugs including enzalutamide and talazoparib before its sale to Pfizer in 2016; earlier, he founded and led Pro•Duct Health, a medical device company focused on breast cancer diagnostics, which was acquired by Cytyc in 2001. Hung holds an M.D. and trained as an academic hematologist-oncologist.
DH
David HanleyinChief Technical Operations Officer
GH
Gary HattersleyinChief Scientific Officer
SM
Stacy MarkelinChief People Officer
PS
Philippe SauvageinChief Financial OfficerHe brings finance, marketing, and operations experience across public and private sector roles in the US, Europe, and Asia, with expertise in systems transformation including CRM, SAP implementations, and M&A.
CS
Colleen SjogreninChief Commercial OfficerShe has experience designing and building out commercial organizations and launching therapies in the oncology space.
KW
Kerry WentworthinChief Regulatory OfficerHe brings expertise in drug development, US and international regulatory affairs, and biologic and drug manufacturing.
SD
Stephen DanginChief Legal OfficerHe brings experience in pharmaceutical and biotech legal matters across drug discovery, development, commercialization, and generic entry.
Board
MD
CN
KB
Kim BlickenstaffBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$275.3M disclosed across 1 of 2 rounds · 2019–2026
▶$275.3MraisedOct 2020 · 57 investors · PharmaceuticalsRule 506(b)
▶$275.3MraisedOct 2020 · 57 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David Hung, M.D.Executive Officer, Director
- Kim BlickenstaffDirector
- Michelle DoigDirector
- Kathryn E. FalbergDirector
- Claudio NessiDirector
- W. Anthony VernonDirector
- Daniel WelchDirector
- Robert BazemoreDirector
- Offering amount
- $275.3M
- Amount sold
- $275.3M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Nuvation Bio Surges In Global Coverage - Aromatherapy Naturalsaromatherapynaturals.com · Aug 2026
Nuvation Bio (NUVB) Stock Rises On IBTROZI Growth And Deeper Losses - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Nuvation Bio do?
- Nuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients. Founded in 2018, it became a commercial-stage company in 2025.
- Who founded Nuvation Bio?
- Nuvation Bio was founded by David Hung, David Hung, M.D. in 2018.
- Who are Nuvation Bio's investors?
- Nuvation Bio's investors include Aisling Capital, Decheng Capital, EcoR1 Capital, Vertex Ventures China, Omega Funds.
- How much funding has Nuvation Bio raised?
- Nuvation Bio has disclosed $275.3M raised across 1 of its 2 known rounds.
- Where is Nuvation Bio headquartered?
- Nuvation Bio is headquartered in New York, US.